Full history for every metric is available with a Kvantra account
F-star Therapeutics, Inc. (FSTX)
Key financial summary
Financials in USD| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 0 | 28 | 11 | 21 | 21 |
| Operating profit | $m | -31 | -37 | |||||
| Net profit | $m | -17 | -28 | -23 | -23 | -26 | -31 | -45 |
| EPS reported | $ | -1.88 | -2.08 | |||||
| Operating cashflow per share | $ | -1.64 | -1.64 | |||||
| Capex per share | $ | 0.04 | 0.04 | |||||
| FCF per share | $ | -1.68 | -1.68 | |||||
| Free cash flow | $m | -28 | -38 | |||||
| Net debt | $m | -65 | -26 | |||||
| Book value equity | $m | 97 | 57 | |||||
| Book value per share | $ | 5.82 | 2.61 | |||||
| Number of shares | m | 16.65 | 21.86 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 0.86 | 2.75 | |||||
| P/S LTM | x | 3.95 | 7.39 | |||||
| P/FCF LTM | x | -2.99 | -4.10 | |||||
| EV/EBITDA LTM | x | -0.62 | -2.95 | |||||
| EV/Sales LTM | x | 0.86 | 6.18 | |||||
| Earnings Yield LTM | % | -37.43% | -26.39% | |||||
| FCF Yield | % | -33.41% | -24.40% | |||||
| Quality | ||||||||
| ROE | % | -32.30% | -44.74% | |||||
| ROIC | % | -27.15% | -27.15% | |||||
| Operating margin | % | -145.10% | -145.10% | |||||
| Gross margin | % | 100.00% | 100.00% | |||||
| FCF/Sales | % | -131.93% | -131.93% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | +88.05% | +452.73% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -2.11 | -3.01 | |||||
| Net Debt/EBITDA | x | 2.22 | 2.22 | |||||
| EBIT/Net interest | x | -36.39 | -36.39 | |||||
| Net debt/market cap | % | -78.16% | -16.44% | |||||
| Net debt/Equity | x | -0.67 | -0.45 | |||||
| Gross debt/equity | x | 0.14 | 0.22 | |||||
Company overview
F-star Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to inventing tetravalent bispecific antibodies for the treatment of cancer, particularly within the field of immuno-oncology. The company's primary investigational product, FS118, is currently in a Phase 2 proof-of-concept trial, evaluating its efficacy in head and neck cancer patients who have acquired resistance to PD-1/PD-L1 therapies. F-star is also advancing FS222, a bispecific antibody designed to simultaneously target the costimulatory CD137 receptor and the inhibitory PD-L1 ligand, through its initial Phase 1 human clinical study. Moreover, two additional drug candidates, FS120 and SB 11285, are undergoing Phase 1 clinical evaluation for patients with advanced malignancies. Founded in 2002, F-star Therapeutics, Inc. has its corporate headquarters situated in Cambridge, United Kingdom.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
F-star Therapeutics, Inc. (FSTX)
F-star Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to inventing tetravalent bispecific antibodies for the treatment of cancer, particularly within the field of immuno-oncology. The company's primary investigational product, FS118, is currently in a Phase 2 proof-of-concept trial, evaluating its efficacy in head and neck cancer patients who have acquired resistance to PD-1/PD-L1 therapies. F-star is also advancing FS222, a bispecific antibody designed to simultaneously target the costimulatory CD137 receptor and the inhibitory PD-L1 ligand, through its initial Phase 1 human clinical study. Moreover, two additional drug candidates, FS120 and SB 11285, are undergoing Phase 1 clinical evaluation for patients with advanced malignancies. Founded in 2002, F-star Therapeutics, Inc. has its corporate headquarters situated in Cambridge, United Kingdom.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free